Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 14

1.

Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.

Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, Pomper MG.

Bioconjug Chem. 2012 Dec 19;23(12):2377-85. doi: 10.1021/bc3003919. Epub 2012 Dec 4.

2.

Essential parameters to consider for the characterization of optical imaging probes.

Leung K, Chopra A, Shan L, Eckelman WC, Menkens AE.

Nanomedicine (Lond). 2012 Jul;7(7):1101-7. doi: 10.2217/nnm.12.79.

3.

A low molecular weight PSMA-based fluorescent imaging agent for cancer.

Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, Pomper MG.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):624-9. doi: 10.1016/j.bbrc.2009.10.017. Epub 2009 Oct 8.

4.

Fluorescent peptide probes for in vivo diagnostic imaging.

Tung CH.

Biopolymers. 2004;76(5):391-403.

PMID:
15389488
5.

Lighting up tumors with receptor-specific optical molecular probes.

Achilefu S.

Technol Cancer Res Treat. 2004 Aug;3(4):393-409. Review.

PMID:
15270591
6.

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Ghosh A, Heston WD.

J Cell Biochem. 2004 Feb 15;91(3):528-39. Review.

PMID:
14755683
7.

124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM.

J Nucl Med. 2003 Dec;44(12):1962-9.

8.

Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging.

Ntziachristos V, Bremer C, Weissleder R.

Eur Radiol. 2003 Jan;13(1):195-208. Epub 2002 Jul 19. Review.

PMID:
12541130
9.

Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer.

Feneley MR, Jan H, Granowska M, Mather SJ, Ellison D, Glass J, Coptcoat M, Kirby RS, Ogden C, Oliver RT, Badenoch DF, Chinegwundoh FI, Nargund VH, Paris AM, Britton KE.

Prostate Cancer Prostatic Dis. 2000 Jul;3(1):47-52.

10.

Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.

Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD.

Prostate Cancer Prostatic Dis. 2002;5(2):132-5.

11.

Transport of molecules, particles, and cells in solid tumors.

Jain RK.

Annu Rev Biomed Eng. 1999;1:241-63. Review.

PMID:
11701489
12.

Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands.

Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, Wiedenmann B, Grötzinger C.

Nat Biotechnol. 2001 Apr;19(4):327-31.

PMID:
11283589
13.

Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.

O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL, Heston WD.

Prostate. 2000 Oct 1;45(2):149-57.

PMID:
11027414
14.

Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase).

Luthi-Carter R, Barczak AK, Speno H, Coyle JT.

J Pharmacol Exp Ther. 1998 Aug;286(2):1020-5.

Supplemental Content

Support Center